Page 187 - Livre électronique des RFTP 2023

P126. CLINICAL AND PHYSIOLOGICAL IMPLICATIONS OF

SHORT ACTING Β-2AGONISTS OVERUSE IN ASTHMA

M. ABDESSLEM1, F. GUEZGUEZ1,2, N . BEN LAZREG1, I . GHANNOUCHI1,2, W.
BENZARTI3, S. ROUATBI1

1UNIVERSITY OF SOUSSE, FARHAT HACHED HOSPITAL, PHYSIOLOGY AND FUNCTIONAL
EXPLORATIONS DEPARTMENT, SOUSSE, TUNISIA.

2UNIVERSITY OF SOUSSE, FARHAT HACHED HOSPITAL, HEART FAILURE (LR12SP09)
RESEARCHLABORATORY, SOUSSE, TUNISIA.
3UNIVERSITY OF SOUSSE, FARHAT HACHED HOSPITAL, PNEUMOLOGYDEPARTMENT, SOUSSE,
TUNISIA.

INTRODUCTION : Asthma is a common disease that affects the respiratory
system. Regular use of controller treatment which reduces inflammation is the base
of an effective asthma management and reliever medication should only be used
to treat acute symptoms. Yet, there is a concern about overreliance of asthma
patients on reliever medication such as Short Acting Beta-2 Agonists (SABA) at the
cost of adequate controller treatment.

This study aimed to investigate the clinical, biological, and physiological
implications of SABA overuse.

PATIENTS AND METHODS : This was a cross-sectional study including 63 asthma
patients referred to the Pulmonary Functional Tests Department. SABA overuse was
defined by the use of more than a canister per month and patients were divided
accordingly into two groups: Over users of SABA (G1; n= 27) and non-over users of
SABA (G2; n= 36). Anthropometric and clinical characteristics were assessed by a
standard medical questionnaire. Anxiety and depression were assessed using the
HADs questionnaire. Quality of life was assessed using the mini AQLQ. All patients
underwent a spirometry with measurement of Forced Vital Capacity (FVC), Forced
Expiratory Volume in one second (FEV1), and a Complete Blood Count (CBC). Data
entry and analysis were performed using the SPSS software and level of
significance was set at p<0.05.

RESULTS : Sex ratio was 0.46. Mean age and mean BMI were 43.59±12.62 years and
29.84±6.31kg/m2, respectively. Compared to G2, G1 had a higher prevalence of
severe asthma (58.3% vs. 38.9%), more severe exacerbations (3(1-5) vs. 1(0-3),
p=0,032). G1 Patients also had worse QOL with a lower score of mini-AQLQ
(51.83±13.60 vs 65.22±21.55; p=0.09) and more depression (69.6%vs30.6%; p=0.003).
In addition, G1 had a more impaired lung function with a FEV1 and a FVC being
significantly lower in G1 compared to G2 (59.93±16.89% vs. 69.33±13.50%; p=0.017)
and (73.28±15.60% vs. 81.42±13.05%; p=0.028), respectively. G1 showed more
eosinophilic inflammation with higher blood eosinophilia level (522.64±639.49
cells/µL vs. 280.82±224.37 cells/µL; p=0.039).

185 | P ag e